Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BSGM NASDAQ:COCH NYSE:INFU NASDAQ:LUNG On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBSGMBiosig Technologies$4.29-7.1%$6.46$0.23▼$14.11$126.10M1.651.58 million shs628,908 shsCOCHEnvoy Medical$1.45-1.0%$1.51$1.21▼$3.99$31.14M2.2127,995 shs4,272 shsINFUInfuSystem$5.70+1.8%$5.94$4.61▼$9.97$119.79M1.81151,030 shs92,083 shsLUNGPulmonx$1.61-12.5%$2.91$1.59▼$9.37$74.07M0.43649,469 shs1.87 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBSGMBiosig Technologies-7.14%-10.44%-55.54%+213.14%+933.73%COCHEnvoy Medical-1.03%-7.37%-3.67%+6.64%-32.48%INFUInfuSystem+1.79%-5.16%-7.62%+17.53%-17.39%LUNGPulmonx-12.50%-51.80%-40.81%-57.29%-76.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBSGMBiosig Technologies2.0956 of 5 stars3.50.00.00.02.50.80.6COCHEnvoy Medical1.9376 of 5 stars3.52.00.00.00.43.30.0INFUInfuSystem2.8399 of 5 stars2.03.00.00.02.64.21.9LUNGPulmonx3.855 of 5 stars4.33.00.00.02.33.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBSGMBiosig Technologies 3.00Buy$10.00133.10% UpsideCOCHEnvoy Medical 3.00Buy$9.25540.14% UpsideINFUInfuSystem 4.00Strong Buy$12.50119.30% UpsideLUNGPulmonx 2.56Moderate Buy$7.66376.04% UpsideCurrent Analyst Ratings BreakdownLatest COCH, LUNG, INFU, and BSGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025LUNGPulmonxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $3.007/31/2025LUNGPulmonxLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.007/31/2025LUNGPulmonxStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $5.007/31/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $16.007/31/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$9.00 ➝ $2.507/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/6/2025BSGMBiosig TechnologiesAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.50 ➝ $10.005/27/2025COCHEnvoy MedicalAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.25 ➝ $9.505/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/8/2025INFUInfuSystemB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBSGMBiosig Technologies$40K2,927.93N/AN/A($0.09) per share-47.67COCHEnvoy Medical$220K140.10N/AN/A($0.88) per share-1.64INFUInfuSystem$137.58M0.87$0.45 per share12.79$2.47 per share2.31LUNGPulmonx$83.79M0.77N/AN/A$2.17 per share0.74Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBSGMBiosig Technologies-$10.33MN/A0.00N/AN/AN/A-5,336.99%-398.16%8/13/2025 (Estimated)COCHEnvoy Medical-$20.80M-$1.38N/AN/AN/A-10,961.26%N/A-233.08%8/11/2025 (Estimated)INFUInfuSystem$870K$0.1495.0218.39N/A1.12%2.78%1.41%N/ALUNGPulmonx-$56.39M-$1.43N/AN/AN/A-62.88%-66.36%-35.51%N/ALatest COCH, LUNG, INFU, and BSGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ABSGMBiosig Technologies-$0.04N/AN/AN/AN/AN/A8/11/2025N/ACOCHEnvoy Medical-$0.30N/AN/AN/AN/AN/A7/31/2025Q2 2025COCHEnvoy Medical-$0.29-$0.32-$0.03-$0.32$0.07 million$0.08 million7/30/2025Q2 2025LUNGPulmonx-$0.40-$0.38+$0.02-$0.38$23.46 million$23.86 million5/19/2025Q1 2025BSGMBiosig Technologies-$0.05-$0.14-$0.09-$0.14N/AN/A5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBSGMBiosig TechnologiesN/AN/AN/AN/AN/ACOCHEnvoy MedicalN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBSGMBiosig TechnologiesN/A2.372.37COCHEnvoy MedicalN/A1.090.88INFUInfuSystem0.501.981.59LUNGPulmonx0.384.974.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBSGMBiosig Technologies7.16%COCHEnvoy Medical8.59%INFUInfuSystem71.13%LUNGPulmonx91.04%Insider OwnershipCompanyInsider OwnershipBSGMBiosig Technologies17.03%COCHEnvoy Medical58.90%INFUInfuSystem11.40%LUNGPulmonx6.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBSGMBiosig Technologies5027.30 million22.65 millionNo DataCOCHEnvoy Medical3421.33 million8.77 millionNot OptionableINFUInfuSystem41021.02 million19.10 millionOptionableLUNGPulmonx25040.26 million37.52 millionOptionableCOCH, LUNG, INFU, and BSGM HeadlinesRecent News About These CompaniesLake Street Capital Cuts Pulmonx (NASDAQ:LUNG) Price Target to $8.00August 1 at 7:24 PM | marketbeat.comPulmonx Corporation (NASDAQ:LUNG) Q2 2025 Earnings Call TranscriptAugust 1 at 6:52 PM | msn.comStifel Nicolaus Cuts Pulmonx (NASDAQ:LUNG) Price Target to $5.00August 1 at 1:05 PM | marketbeat.comPulmonx (NASDAQ:LUNG) Given New $16.00 Price Target at D. Boral CapitalAugust 1 at 9:32 AM | marketbeat.comPulmonx (NASDAQ:LUNG) Rating Lowered to "Neutral" at Piper SandlerAugust 1 at 7:53 AM | marketbeat.comPiper Sandler Downgrades Pulmonx (LUNG)July 31 at 10:54 PM | msn.com7LUNG : Analyst Expectations For Pulmonx's FutureJuly 31 at 5:54 PM | benzinga.comPulmonx slumps as Piper Sandler downgrades despite Q2 beatJuly 31 at 5:54 PM | msn.comPulmonx Corporation (NASDAQ:LUNG) Given Average Rating of "Moderate Buy" by BrokeragesJuly 31 at 2:44 AM | americanbankingnews.comPulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of "Moderate Buy" by BrokeragesJuly 31 at 2:44 AM | marketbeat.comPulmonx Corporation (LUNG) Q2 2025 Earnings Call TranscriptJuly 30 at 11:02 PM | seekingalpha.comPulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue EstimatesJuly 30 at 7:01 PM | zacks.comPulmonx Reports Second Quarter 2025 Financial ResultsJuly 30 at 4:05 PM | globenewswire.comPulmonx to Present at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30 at 9:20 AM | manilatimes.netMEssex Investment Management Co. LLC Makes New Investment in Pulmonx Corporation (NASDAQ:LUNG)July 30 at 4:20 AM | marketbeat.comLegato Capital Management LLC Takes $606,000 Position in Pulmonx Corporation (NASDAQ:LUNG)July 25, 2025 | marketbeat.comPulmonx (LUNG) to Release Earnings on WednesdayJuly 23, 2025 | marketbeat.comPulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025July 16, 2025 | globenewswire.comPulmonx Corporation (NASDAQ:LUNG) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 6, 2025 | marketbeat.comPulmonx Corporation (NASDAQ:LUNG) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 6, 2025 | marketbeat.comRichard Ferrari Sells 8,000 Shares of Pulmonx Co. (NASDAQ:LUNG) StockJune 14, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?By Leo Miller | July 31, 2025View Spotify's Q2 Earnings Plunge: An Opportunity or Ominous Signal?COCH, LUNG, INFU, and BSGM Company DescriptionsBiosig Technologies NASDAQ:BSGM$4.29 -0.33 (-7.14%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.32 +0.04 (+0.82%) As of 08/1/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioSig Technologies, Inc., together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with Mayo Foundation to develop an AI- and machine learning-powered software for PURE EP system. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.Envoy Medical NASDAQ:COCH$1.44 -0.02 (-1.03%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$1.46 +0.02 (+1.38%) As of 08/1/2025 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.InfuSystem NYSE:INFU$5.70 +0.10 (+1.79%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.70 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.Pulmonx NASDAQ:LUNG$1.61 -0.23 (-12.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.67 +0.06 (+3.66%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
